Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255848 | 0.86 | MAPT (0.62) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL161315 | 0.85 | SMN1; SMN2 (0.61) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15655480 | 0.84 | MEN1 (0.59) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8069465 | 0.84 | SCN9A (0.81) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15217707 | 0.82 | MAPT (0.58) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16433005 | 0.80 | ALDH1A1 (0.58) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2000832 | 0.80 | SMN1; SMN2 (0.62) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL882668 | 0.78 | HSD17B10 (0.56) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10995653 | 0.78 | HPGD (0.46) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20301363 | 0.78 | SMN1; SMN2 (0.52) | POLBMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927711-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | POLB 1797/4885MAPT 2693/4885SMN1; SMN2 2411/4885 |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | POLB 2985/4885MAPT 3086/4885SMN1; SMN2 2798/4885 |
| US-20130225614-A1 | 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | POLB 2138/4885MAPT 3421/4885SMN1; SMN2 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.